The overall aim of the BREATHER trial is to evaluate the role of Short-Cycle Therapy (SCT) in the management of HIV-infected young people who have responded well to antiretroviral therapy (ART) and to determine whether young people with chronic HIV infection undergoing Short-Cycle Therapy of five days on ART and two days off maintain the same level of viral load suppression as those on continuous therapy, over 48 weeks.
Approximately 100 patients will be enrolled in each study arm, followed initially for 48 weeks. Additional long term follow up will be conducted subsequently for two years.
View Project Publications here
This study is funded by Penta.